Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Eva‐Maria Grischke | Researchclopedia

Back to researchers

Eva‐Maria Grischke

Universitätsklinikum Tübingen ORCID

370

Works

43,175

Citations

38

h-index

98

i10-index

Research Topics

HER2/EGFR in Cancer Research Breast Cancer Treatment Studies Ovarian cancer diagnosis and treatment

Affiliations

German Society of Surgery1996–1996

Heidelberg University1999–2013

Norfolk and Norwich University Hospital2021–2021

Universitair Ziekenhuis Leuven2017–2017

University Hospital Heidelberg1987–2013

Top Works

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Andreas D. Hartkopf,Florin‐Andrei Taran,et al.

201630,896 citations

Advanced Breast Cancer Therapies

BRCA gene mutations in cancer

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Gabriel N. Hortobágyi,Salomon M. Stemmer,et al.

20161,957 citations

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

E O’Brien,Nely Wigler,et al.

20041,703 citations

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

George W. Sledge,Masakazu Toi,et al.

20171,623 citations

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

George W. Sledge,Masakazu Toi,et al.

2019964 citations

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain,David Miles,et al.

2020866 citations

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

S. Loibl,Michael Untch,et al.

2019674 citations

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Jacobus Pfisterer,Catherine Shannon,et al.

2020158 citations

De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor–Positive Phase II Randomized Trial—Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET

Nadia Harbeck,Oleg Gluz,et al.

2017148 citations